Skip to main content
. Author manuscript; available in PMC: 2019 Jan 18.
Published in final edited form as: Mol Cell. 2018 Jan 18;69(2):279–291.e5. doi: 10.1016/j.molcel.2017.12.024

Figure 7. EZH2 Phosphorylation at T311 Correlates with Better Survival in Cancer Patients.

Figure 7

(A–B) Immunohistochemical staining of p-T172-AMPKα and p-T311-EZH2 in representative ovarian cancer (A) or breast cancer (B) specimens. Brown staining indicates positive immunoreactivity.

(C–D) A positive correlation between p-T172-AMPKα and p-T311-EZH2 levels in human ovarian cancer (C) or breast cancer (D) clinical samples. Statistical significance was determined by a χ2 test.

(E–F) Kaplan–Meier curves showing the overall survival of patients with high or low expression of p-T311-EZH2 in their ovarian cancer (E) or breast cancer (F). Statistical significance was determined by a log-rank test.

See also Figure S7.